Clinical Textbook of Addictive Disorders 3rd ed - R. Frances, S. Miller, A. Mack (Guilford, 2005) WW

10. Sedatives/Hypnotics and Benzodiazepines 241(Eds.), Principles of addiction medicine (3rd ed., pp. 977–985). Chevy Chase, MD:American Society of Addiction Medicine.Medical Economics Data Production. (2003). Physicians’ desk reference. Montvale, NJ:Author.Mellinger, G. D., & Balter, M. B. (1981). Prevalence and patterns of use of psychotherapeuticdrugs: Results from a 1979 national survey of American adults. In G.Tognoni, C. Bellantuono, & M. Lader (Eds.), Epidemiological impact of psycho-tropicdrugs (pp. 117–135). Amsterdam: Elsevier.Mendelson, W. B., Roth, T., Casella, J., Roehrs, T., Walsh, J., Woods, J. H., et al.(2001). Report on a conference: The treatment of chronic insomnia: Drug indication,chronic use and abuse liability. Paper presented at the NCDEU meeting, Phoenix,AZ.Noyes, R., Garvey, M. J., Cook, B. L., & Perry, P. J. (1988). Benzodiazepine withdrawal:A review of the evidence. J Clin Psychiatry, 49, 382–389.Rickels, K., Schweizer, E., Csanalosi, I., Case, G. W., & Chung, H. (1988). Long-termtreatment of anxiety and risk of withdrawal. Arch Gen Psychiatry, 45, 444–450.Ross, J. (1994). Triumph over fear: A book of help and hope for people with anxiety, panicattacks, and phobias. New York: Bantam.Sattar, S. P., & Bhatia, S. (2003). Benzodiazepines for substance abusers. Curr Psychiatry,l2(5), 25–34.Savage, S. R. (2003). Principles of pain management in the addicted patient. In A. W.Graham, T. K. Schultz, M. F. Mayo Smith, & R. K. Ries (Eds.), Principles of addictionmedicine (3rd ed., pp. 1405–1419). Chevy Chase, MD: American Society ofAddiction Medicine.Scharf, M. B., Mayleben, D. W., Kaffeman, M., Krall, R., & Ochs, R. (1991). Doseresponse effects of zolpidem in normal geriatric subjects. J Clin Psychiatry, 52, 77–83.Schenck, C. H., & Mahowald, M. W. (1996). Long-term, nightly benzodiazepine treatmentof injurious parasomnias and other disorders of disrupted nocturnal sleep in170 adults. Am J Med, 100, 333–337.Sellers, E. M., Ciraulo, D. A., DuPont, R. L., Griffiths, R. R., Kosten, T. R., Romach,M. K., & Woody, G. E. (1993). Alprazolam and benzodiazepine dependence. J ClinPsychiatry, 54(Suppl), 64–74.Spencer, E. D., DuPont, R. L., & DuPont, C. M. (2004). The anxiety cure for kids: Aguide for parents. New York: Wiley.Stahl, S. M. (2003). At long last, long-lasting psychiatric medications: An overview ofcontrolled-released technologies. J Clin Psychiatry, 64, 4.Sussman, N., & Stein, D. J. (2002). Pharmacotherapy for generalized anxiety disorder.In D. J. Stein & E. Hollander (Eds.), Textbook of anxiety disorders (pp. 135–141).Washington, DC: American Psychiatric Press.Tyrer, P., Rutherford, D., & Huggett, D. (1981). Benzodiazepine withdrawal symptomsand propranolol. Lancet, 1, 520–522.U.S. Department of Health and Human Services. (2001, March). Monitoring theFuture—overview of key findings (NIH Publication No. 02-5105). Rockville, MD:National Institutes of Health, National Institute on Drug Abuse.U.S. Department of Health and Human Services. (2002). Results from the 2001 NationalHousehold Survey on Drug Abuse (DHHS Publication No. SMA 02-3758). Rock-